AUG 2 2 2006 IN THE UNIT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

For: PRO269 POLYPEPTIDES	Customer No. 35489
Filed: July 12, 2001	Attorney's Docket No. 39780-1618 P2C33
Application Serial No. 09/904,766	Confirmation No: 4054
Avi Ashkenazi, et al.	Art Unit: 1646
In re application of:	Examiner: Kemmerer, Elizabeth

EXPRESS MAIL LABEL NO. EV 582 632 169 US

Date Mailed: August 21, 2006

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

MAIL STOP RCE

Commissioner for Patents PO Box 1450 Alexandria, Virginia 22313-1450

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy of each listed publication and U.S. and foreign patent, except for pending U.S. applications, is being submitted herewith, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §1.97-1.98.

Applicants note that some of the references listed in the Information Disclosure Statement are provided in the form of full-text articles, while others are provided as abstracts. Applicants submit that the full-text articles are provided <u>solely</u> because they are available to Applicants. Applicants do not intend to make any distinction among the references, or to indicate that some references in the IDS are more pertinent or material than others.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If Form PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with M.P.E.P. §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

\bowtie	This sta	itement qualifie	s under 37 C.F.R. §1.9	//, subsection (b) b	ecause (cneck all th	at apply):
	_ ·	(1) than a	It is being filed withit continued prosecution OR	in 3 months of the a application under	application filing da § 1.53(d)	ite and is other
		(2)	It is being filed within OR	in 3 months of entr	y of a national stage	•
		(3) merits	It is being filed before OR	re the mail date of t	he first Office Action	on on the
•	\boxtimes	(4) of a re-	It is being filed before quest for continued ex-			after the filing
	filing d stage as action of	ate of a national set forth in §1. on the merits, but	this statement is being application; (2) three 491 in an international the before the mailing defender §1.311, then:	months beyond the lapplication; or (3)	e date of entry of the the mailing date of	e national f a first Office
		a certification	as specified in §1.97(e) is provided below	; or	
		a fee of \$180.0 the payment of	on as set forth in §1.176 other papers filed tog	(p) is authorized be ether with this state	low, enclosed, or insement.	icluded with
:	37 C.F. office a fee, the	ction under §1.	this statement is being 113 or a notice of allow	filed after the mail wance under §1.311	ing date of the earl, but before payme	ier of a final int of the issue
	A.	a certification	as specified in §1.97(e) is completed belo	w; and	
	B.	a petition unde submitted here	r 37 C.F.R. §1.97(d) rewith; and	equesting considera	ition of this stateme	nt is
	C.	a fee of \$130.0 the payment of	0 as set forth in §1.176 other papers filed tog	(i)(1) is authorized ether with this state	below, enclosed, or ement.	included with
\boxtimes	of \$0.0	0 and charge an	e Commissioner is her y additional fees or creosit Account No. <u>08-1</u>	edit any overpayme	ent associated with t	his
			Resi	pectfully submitted	,	
Dated:	August	21, 2006	By:_	Leslie Mooi, Reg.	<u>7</u> 620 No. 37,047	. *

HELLER EHRMAN LLP

275 Middlefield Road

Menlo Park, California 94025-3506

Telephone: (650) 324-7000 Facsimile: (650) 324-0638

		Form PT0	D-1449	Attorney's Docket No. 39780-1618P2C33	Ap	plication Se /904,766	rial No	
INFORMATION DISCLOSURE STATEMENT		Applicant(s) Avi Ashkenazi et al.						
	(use se	veral shee	ts if necessary)	Filing Date: July 12, 2001	Gr	oup Art Utilit	: ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~	
· · · ·	100000			J.S. PATENT DOCUMENTS			PADEMARK	37/
Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date (if appropr	•
				DEION DATENT DOCUMENTS				- 35.
660 112	T = -			REIGN PATENT DOCUMENTS	Class	Subclass	Transla	ation
Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Jubilass	YES	NO
<u> </u>	 					 		_
\$ K.		# 1 (* t)	(including	OTHER DOCUMENTS author, title, date, pertinent page	es, etc.)			
Examiner Initials	Ref. No.	Title						
	1.	Pancreat	tic Exocrine Tissue." Br J	Mobility Group A2 Expression L Cancer - <u>89(11)</u> :2104-9 (2003) Ab	ostract.			
	2.	(2005) Al	bstract.	sis of Natural Killer-Cell Tumour				
	3.	Metallop	roteinase Inhibitor-1 Mess	arcinoma Cell Lines and Normal enger-RNA and Protein," <i>Thyroi</i>	id - <u>7(5)</u> :713-24 (199	7) Abstract.		
	4.	Barnes, V.L., et al., "Expression of Embryonic Fibronectin Isoform EllIA Parallels Alpha-Smooth Muscle Act Maturing and Diseased Kidney," J Histochem Cytochem 47(6):787-98 (1999) Abstract.						
	5.	Cell I vm	phonas." Cancer Res 61	cation and Overexpression in H				
	6.	Samples Methods	and Monocyte-Derived Dec 246(1-2):79-90 (2000) Al	ation of Proinflammatory and Cl endritic Cells: Validation of a Ne ostract.	w Real-Time RT-PC	R Technology	," J Immuno	
	7.	Buckley,	A.R., et al., "Butyrate-Ind	uced Reversal of Dexamethason 97) Abstract.				
	8.	Caberlot Genetic	to, L. <i>et al.,</i> "Alterations in Animal Model of Depressi	Neuropeptide Y Levels and Y1 E on," <i>Neurosci Lett.</i> - <u>265(3)</u> :191-	4 (1999) Abstract.			
	9.	Brain." E	Eur J Neurosci 17(9):173	Receptor and Relative Abundar 6-46 (2003) Abstract.				
	10.	(2002) AI	bstract.	f Cyclin D2 Expression in Huma				
	11.	Arch 4	145(3):279-84 (2004) Abstra	ionic Gonadotrophin Beta Expre act.				
	12.	Dagenais Physio L	s, A., <i>et al.,</i> "Downregulati .ung Cell Mol Physiol 28	on of EnaC Activity and Express (6(2):L301-11 (2004) Abstract.	· _			
	13.	De Boer,	C.J., et al., " Involement of	of the CCNDI Gene in Hairy Cell I	Leukemia," Ann On	col <u>7(3</u>):251	-6 (1996) Abs	stract.
	14.	Mol Hum	Reprod 6(8):743-9 (200)	ivin Production and Subunit Exp 0) Abstract.				
	15.	Dong, Z.	, et al., "Expression of Me	mbrane-Type Matrix Metalloproto Sci - <u>42(13)</u> :3223- (2001) Abstra	einases 4, 5, and 6 i ect.	n Mouse Corr	eas Infected	with P.
EXAMINE	R·			DATE CONSID	ERED:			## - 1 Yan

EXAMINER: Initial if citation considered, whether or not the citation con-	forms with MPEP 609. Draw a line through the citation if not in
conformance and not considered. Include a copy of this form with next	communication to applicant.
*If an asterisk is placed beside the reference number, a copy is not provi	ded because the reference was previously cited by or submitted to the
PTO in a prior application that is identical in the statement and relied upon	on for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.96 (u).
SV 2228326 v1	

Form PTO-1449	Attorney's Docket No. 39780-1618P2C33	Application Serial No. 09/904,766
INFORMATION DISCLOSURE STATEMENT	Applicant(s)	
		Ashkenazi et al.
(use several sheets if necessary)	Filing Date: July 12, 2001	Group Art Unit: 1646
	OTHER DOCUMENTS	
	author, title, date, pertinent pages, etc	
Transcriptase-Polymerase Chain R	f Proliferative Activity in Colorectal Ca eaction (RT-PCR)," <i>Cancer Invest.</i> - <u>19</u>	9(6):588-96 (2001) Abstract.
Equine Vet J 34(4):349-58 (2002)	Equine vet J 34(4):349-36 (2002) Abstract.	
Implications for Th Cell Lineage Co	Equation C.E. et al. "Suppressors of Cytokine Signaling Proteins are Differentially Expressed in Th1 and Th2 Cells:	
19. Vitreoretinopathy," Br J Opthalmol	Invading Cells Contribute to Vitreal Cy <u>85(4)</u> :461-70 (2001) Abstract.	
20. Eleore, L., et al., "Modulation of the Transporter 2 in the Rat Facial Nuc	Glutamatergic Receptors (AMPA and leus after Axotomy," Neuroscience	NMDA) and of Glutamate Vesicular 136(1):147-60 (2005) Abstract.
21. Forsberg, H., et al., "Altered Levels Radic Res 24(6):451-9 (1996) Abs	of Scavenging Enzymes in Embryos stract.	Subjected to a Diabetic Environment," Free
Priminary Cultures of Rat Hepatocy	rtes," Endocrinology - 133(4):1548-54	
23. Profiling," Blood - 106(13):4315-21	(2005) Abstract.	ologic Study Based on Gene Expression
Cycle," Biol Reprod 54(3):700-8 (1996) Abstract.	nd Gene Expression During the Estrous
25. Furuta, J., et al., "Silencing of the T (2005) Abstract.	hrombomodulin Gene in Human Malig	gnant Melanoma," <i>Melanoma Res.</i> - <u>15(1)</u> :15-20
26. Futcher, B., et al., "A Sampling of the	he Yeast Proteome," <i>Mol Cell Biol.,</i> - <u>1</u>	<u>9(11)</u> :7357-68 (1999) Abstract.
27. Changes of Individual P450 Enzyme Abstract.	es Among Patients with Cirrhosis," <i>Bi</i>	es is Responsible for Disease-Specific ochem Pharmacol <u>49(7)</u> :873-81 (1995)
26. 165(7):3985-91 (2000) Abstract.		lation by Protein Kinase C-alpha," <i>J immunol</i>
^{29.} Expression." <i>Blood</i> - 101(6):2285-93	Profiling of Human Platelets Using Mic 3 (2003) Abstract.	
30. Godbout, R., et al., "Overexpressio Biol Chem 273(33):21161-8 (1998)	n of DEAD Box Protein (DDX1) in Neur Abstract.	roblastoma and Retinoblastoma Cell Lines," J
31. Goldenberg, R.C., et al., "Modulation Endocrinol 177(2):327-35 (2003) A	on of Gap Junction Mediated Intercellu	ular Communication in TM3 Leydig Cells," J
32. Golebiowski, F., et al., "Expression Abstract.	Level of Ubc9 Protein in Rat Tissues,	" Acta Biochim Pol <u>50(4)</u> :1065-73 (2003)
33. Grem, J.L., et al., "Thymidine Kinas Lines of the National Cancer Institu	e, Thymidylate Synthase, and Dihydro te's Anticancer Drug Screen," <i>Clin Ca</i>	opyrimidine Dehydrogenase Profiles of Cell nncer Res <u>7(4)</u> :999-1009 (2001) Abstract.
34. Grenback, E., et al., "Galanin Pituita	ary Adenomas," <i>Regul Pept,</i> - <u>117(2)</u> :1	27-39 (2004) Abstract.
Non-Invasive and Invasive Bladder	Transitional Cell Carcinomas," Int J. C	te-Type Fatty Acid Binding Protein Correlate in Oncol 13(2):379-83 (1998) Abstract.
Guo, Y., et al., "The Pathogenic Rol	e of Macrophage Migration Inhibitory Xi Za Zhi - <u>25(6)</u> :337-40 (2002) Abstra	Factor in Acute Respiratory Distress

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	

*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d). SV 2228326 v1

-		Form PTO-1449	Attorney's Docket No.	Application Serial No. 09/904.766	
	D14 4 T10	NI DIOCI COURT CTATEMENT	39780-1618P2C33	09/904,766	
INFORMATION DISCLOSURE STATEMENT		IN DISCLOSURE STATEMENT	Applicant(s) Avi Ashkenazi et al.		
			Filing Date:	Group Art Unit:	
	luse sev	veral sheets if necessary)	July 12, 2001	1646	
			OTHER DOCUMENTS		
		(including au	hor, title, date, pertinent pages, etc		
	37.	Hyperuricemia in the Rat Kidney." Big	ochem Pharmacol - 69(6):993-9 (200	orters rOAT1, rOAT3 and rOCT2 after 05) Abstract.	
	38.	Pharmacol 127(2):187-98 (1994) Abstract.			
	39.	Radioimmunoassay." Breast Cancer	Re <i>s Treat.</i> - <u>24(1)</u> :71-4 (1992) Abstra	ed by pS2-mRNA Analysis and pS2-Protein act.	
	40.	Severe Asthma." Clin Exp Allergy 3	3(2):233-40 (2003) Abstract.	in Sustaining Neutrophil Inflammation in	
	41.	Hassett, C., et al., "Human Hepatic Mi Arch Biochem Biophys 337(2):275-8	crosomal Epoxide Hydrolase: Com _l 33 (1997) Abstract.	parative Analysis of Polymorphic Expression,"	
	42.	Hedge, P., et al., "A Concise Guide to	cDNA Microarray Analysis," BioTec	chniques, <u>29(3)</u> :548-562 (2000).	
	43.	Holten-Andersen, M.N., et al., "Localiz Adenoma and Adenocarcinoma," Int.	ration of Tissue Inhibitor of Metallo	proteinases 1 (TIMP-1) in Human Colorectal stract.	
	44.	Huang, Y.H., et al., "Tissue Plasminog Med Virol 70(4):610-6 (2003) Abstrac	en Activator Induced by Dengue Vi	rus Infection of Human Endothelial Cells," J	
	45.	Huettner, P.C., et al., "Neu Oncogene Expression in Ovarian Tumors: A Quantitative Study," <i>Mod Pathol.</i> - <u>5(3)</u> :250-6 (1992) Abstract.			
	46.	Hui, P., et al., "Real-time Quantitative RT-PCR of Cyclin D1 mRNA in Mantle Cell Lymphoma: Comparison with FISH and Immunohistochemistry," Leuk Lymphoma. 44(8):1385-94 (2003) Abstract.			
·	47.	Husain, I., et al., "Elevation of Topoisomerase I Messenger RNA, Protein, and Catalytic Activity in Human Tumors: Demonstration of Tumor-Type Specificity and Implications for Cancer Chemotherapy," Cancer Res 54(2):539-46 (1994) Abstract.			
	48.	Ihmann, T., et al., "High-level mRNA C Prognosis in Colorectal Carcinoma,"	Quantification of Proliferation Marke J Cancer Res Clin Oncol <u>130(12)</u> :	er pKi-67 is Correlated with Favorable 749-56 (2004) Abstract.	
	49.	Ikegami, T., et al., "Modulation of Gluc Kidney Cells," Am J Physiol Cell Phys	cagon Receptor Expression and Re	sponse in Transfected Human Embryonic	
	50.	Jacquemin, E., et al., "Developmental Retina." Int J Biol 37(3):417-23 (199)	Regulation of Acidic Fibroblast Gro	owth Factor (aFGF) Expression in Bovine	
	51.	Jaime, M., et al., "The p21 (Cip1) Prote CDC25A in Mice Regenerating Livers,	ein, A Cyclin Inhibitor, Regulates the " <i>Hepatology</i> - 35(5):1063-71 (2002)	e Levels and the Intracellular Localization of Abstract.	
	52.	Janssens, N., et al., "Alteration of Friz Abstract.	zled Expression in renal Cell Carcin	noma," <i>Tumour Biol.</i> - <u>25(4)</u> :161-71 (2004)	
	53.	Jungbluth, A.A., et al., "Immunohistor Human Tissues." Int J. Cancer - 92(6)	:856-60 (2001) Abstract.	igen Expression in Normal and Malignant	
;	54.	Kalabis, G.M., et al., "Multidrug Resis Biol Reprod 73(4):591-7 (2005) Abst	tance Phosphoglycoprotein (ABCB ract.	1) in the Mouse Placenta: Fetal Protection,"	
	55.	Kammaori, M., et al., "Expression of Progesterone Receptors, in Breast Tu 27(5):1257-63 (2005) Abstract.	luman Telomerase Reverse Transcr Imors: Preliminary Data from Neo-A	riptase Gene and Protein, and of Estrogen amd Adjuvant Chemotherapy," Int J Oncol.	
	56.	Khal, J., et al., "Expression of the Ubi J Cancer - 93(7):774-80 (2005), Abstra		scle Loss in Experimental Cancer Cachexi," Br	
FXAMINE	·		DATE CONSIDERED:		

EXAMINER:	DATE CONSIDERED:	
EXAMINER: Initial if citation considered, whether or not the citation conformance and not considered. Include a copy of this form with next of	forms with MPEP 609. Draw a line through the citation if not in communication to applicant.	
*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).		
SV 2228326 v1	of for all earlier filling date dilder 55 0.0.0. \$120. 0. 0.1.1. \$1100 (0).	

		Form PTO-1449	Attorney's Docket No. 39780-1618P2C33	Application Serial No. 09/904,766
INFORMATION DISCLOSURE STATEMENT		N DISCLOSURE STATEMENT	Applicant(s)	09/904,700
		N DISCLOSURE STATEMENT		Ashkenazi et al.
			Filing Date:	Group Art Unit:
(1)	(use several sheets if necessary)		July 12, 2001	1646
(including 57. Khal, J., et al., "Increased Express Int J. Biochem Cell Biol 37(10):2			OTHER DOCUMENTS puthor, title, date, pertinent pages, etc.	
			on of Proteasome Subunits in Skeleta	al Muscle of Cancer Patients with Weight Loss,"
			96-206 (2005) Abstract.	
	58.	Kogo, H., et al., "Cell Type-Specific Distinct mRNAs." J Biol Chem 27	Occurrence of Caveolin-1alpha and - 9(24):25574-81 (2004) Abstract.	-1beta in the Lung caused by Expression of
	59.	Kommoss, F., et al., "Oncogene and 155:19-24 (1992) Abstract.	d Growth Factor Expression in Ovaria	in Cancer," Acta Obstet Gynecol Scand Suppl
	60.	Kumar, U., et al., "Somatostatin Receptors in Primary Human Breast Cancer: Quantitative Analysis of mRNA for		
2012 C	61.	Kuo, C.C., et al., "A Transcriptomic Leukemia Cells." Proteomics - 5(4):	894-906 (2005) Abstract.	of CpG-ODN on Human THP-1 Monocytic
	62.	Landmark, B.F., et al., "Cellular Loc Protein Kinase in Rat Testis," J Rep	ation and Age-dependent Changes o prod Fertil 99(2):323-34 (1993) Abstr	f the regulatory Subunits of cAMP-dependent act.
	62.	Lassmann, S., et al., "Quantification Immunohistochemistry Reveals Into	n of CK20 Gene and Protein Expressions of CK20 Gene and Intratumour Heterogeneity," <i>J</i>	on in Colorectal Cancer by RT-PCR and Pathol 198(2):198-206 (2002) Abstract.
	63.	Legrand, O., et al., "Expression of t Peripheral Blood and Bone Marrow	he Multidrug Resistance-Associated Haemopoietic Cells," <i>Br J, Haematol</i>	Protein (MRP) mRNA and Protein in Normal <u>94(1)</u> :23-33 (1996) Abstract.
	64.	Lemstrom, K.B., et al., "Vascular Endothelial Growth Factor Enhances Cardiac Allograft Arteriosclerosis," Circulation - 105(21):2524-30 (2002) Abstract.		
	65.	Li 7.R. et al. "Enhanced Expressions of Arachidonic Acid-Sensitive Tandem-Pore Domain Potassium Channels in Ra		o <u>327(4)</u> :1163-9 (2005) Abstract.
	66.	Li V et al. "Retinal Preconditioning and the Induction of Heat-Shock Protein 27." Invest Ophthalmol Vis Sci		
	67.	Lindherg P. et al. "Increasing Expression of Tissue Plasminogen Activator and Plasminogen Activator Inhibitor Type		
	68.	Macabeo-Ong, M., et al., "Effect of I Reaction Analyses." 15(9):979-87 (2	Duration of Fixation on Quantitative R 2002) Abstract.	Reverse Transcription Polymerase Chain
,-	69.	Maruyama, H., et al., "Id-1 and Id-2 and Pancreatitis." Am J Pathol 155(3):	are Overexpressed in Pancreatic Can :815-22 (1999) Abstract.	cer and in Dysplastic Lesions in Chronic
	70.	Meehan, T.P., et al., "Tightly Regula Cells." J Mol Endocrinol 32(1):247	ated and Inducible Expression of a Yo 7-55 (2004) Abstract.	ked Hormone-Receptor Complex in HEK 293
	71.	Mendoza-Rodriguez, C.A., et al., "C During the Estrous Cycle." Mol Rep	-fos and Estrogen Receptor Gene Exporod Dev. 64(4):379-88 (2003) Abstrac	pression Pattern in the Rat Uterine Epithelium et.
	72.	Meoni, P., et al., "[3H]MK-801 Bindi	ng and the mRNA for the NMDARI Subrain," Brain Res Mol Res 54(1):13-2	bunit of the NMDA Receptor are Differentially
	73.	Mezzano, S.A., et al., "Overexpress Membranous Nephropathy," Kiney	ion of Chemokines, Fibrogenic Cytok	ines, and Myofibroblasts in Human
	74.	Mingrone, G., et al., "Decreased Un Obese Subjects," Obes Res 11(5	coupling Protein Expression and Intr	amyocytic Triglyceride Depletion in Formerly
	75.	Miralles, C.P., et al., "Differential Ex	pression of the Short and Long Form Brain Res Mol Res 24(1-4):129-39	ns of the Gamma 2 Subunit of the (1994) Abstract.
	76.	Mizrachi, D., et al., "Follicle-stimulat	ting Hormone Receptor and Its Messe	enger Ribonucleic Acid are Present in the
EXAMINER:			DATE CONSIDERED	

	E/Aminetti
	EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in
	conformance and not considered. Include a copy of this form with next communication to applicant.
	*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the
	PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).
ш	SV 2228326 v1

	Form PTO-1449	Attorney's Docket No.	Application Serial No.
		39780-1618P2C33	09/904,766
INFORMATI	ON DISCLOSURE STATEMENT	Applicant(s)	Ashkenazi et al.
		Filing Date:	Group Art Unit:
/1150 50	veral sheets if necessary)	July 12, 2001	1646
: 436.30	Bovine Cervix and Can Regulate Cer	rvical Prostanoid Synthesis," Biol Re	prod 61(3):776-84 (1999) Abstract.
· · · · · · · · · · · · · · · · · · ·		OTHER DOCUMENTS	
	(including at	uthor, title, date, pertinent pages, etc	
. 77.	Monaghan, P., et al., "The Alpha(v)b Constitutively on the Epithelial Cells	s Targeted in Cattle," <i>J Gen Virol.</i> - <u>86</u>	6(Pt 10):2769-80 (2005) Abstract.
78.	Montuori, N., et al., "Urokinase-Medi	ated Posttranscriptional Regualtion	of Urokinase-Receptor Expression in Non
	Small Cell Lung Carcinoma," Int J C	elial Growth Factor Expression Corre	elates with Matrix Metalloproteinases MT1-
79.	MMP. MMP-2 and MMP-9 in Human (Glioblastomas," <i>Int J Cancer</i> - <u>106(6)</u> :	848-55 (2003) Abstract.
80.	Nie, Y., et al., "DNA Hypermethylation Esophageal Squamous Cell Carcino	on is a Mechanism for Loss of Expres mas." Carcinogenesis - 22(10):1615-2	sion of the HLA Class I Genes in Human 23 (2001) Abstract.
81.	Nuciforo, P.G., et al., "Molecular and	I Immunohistochemical Analysis of F estract.	IER2/neu Oncogene in Synovial Sarcoma,"
82.	Tissue." Biochem Biophys Res Com	<i>mun.</i> - 214(3):1009-14 (1995) Abstrac	n Well Healing and Chronic Human Wound et.
83.	Orntoft, T.F., et al., "Genome-wide Study of Gene Copy Numbers, Transcripts, and Proteins Levels in Pairs of Non- invasive and Invasive Human Transitional Cell Carcincomas," Mol Cell Proteomics 1(1):37-45 (2002) Abstract.		
84.	Orntoft, T.F., et al. "Genome-Wide Study of Gene Copy Numbers, Transcripts, and Protein Levels in Pairs of Non-Invasive and Invasive Human Transitional Cell Carcinomas," Molecular & Cellular Proteomics – 1:37-45 (2002).		
85.	Pachmann, K., et al., "Expression of bcr-abl mRNA in Individual Chronic Myelogenous Leukaemia Cells as determined by in Situ Amplification," Br J. Haematol - 112(3):749-59 (2001) Abstract.		
	Pairon J.C. et al. "Cell Localization and Regulation of Expression of Cytochrome P450 1A1 and 2B1 in Rat Lung after		
86.	Induction with 3-Methylcholanthrene Using mRNA Hybridization and Immunohistochemistry," Am J Respir Cell Mol Biol - 11(4):386-96 (1994) Abstract.		
	Papotti, M., et al., "Correlative Immu	nohistochemical and Reverse Transc	criptase Polymerase Chain Reaction Analysis
87.	of Somatostatin Receptor Type 2 in Abstract.	Neuroendocrine Tumors of the Lung	," Diagn Mol Pathol <u>9(1)</u> :47-57 (2000)
	Papotti, M., et al., "Expression of So	matostatin Receptor Types 1-5 in 81	Cases if Gastrointestinal and Pancreatic
88.	Endocrine Tumors. A correlative Im	munohistochemical and Reverse-Tra	anscriptase Polymerase Chain Reaction
	Analysis," Virchows Arch 440(5):4	61-75 (2002) Abstract.	Outcome in Invasive Breast Carcinomas and
89.	Faredes, J., et al., "P-Cadnerin Over is Associated with CDH3 Promoter is	expression is an indicator of Clinical Hypomethylation," <i>Clin Cancer Res.</i> -	Outcome in Invasive Breast Carcinomas and 11(16):5869-77 (2005) Abstract.
	Politis, I., et al., "Mammary-Derived	Growth Inhibitor Protein and Messen	ger Ribonucleic Acid Concentrations in
90.	Different Physiological States of the	Gland," J Dairy Sci 75(6):1423-9 (1	992) Abstract.
91.	Preesman, A.H., et al., "T-Cell Reception Hodgkin's Lymphomas." J Invest De	otor V Beta-family Usage in Primary C Cermatol <u>99(5)</u> :587-93 (1992) Abstrac	Cutaneous and Primary Nodal T-cell non- ct.
92.	Pullig, O., et al., "Matrilin-3 in Huma	n Articular Cartilage: Increased Expre	ession in Osteoarthritis," <i>Osteoarthritis</i>
	Rey, C., et al., "Up-regulation of Mitochondrial Peripheral Benzodiazepine Receptor Expression by Tumor Necrosis		e Receptor Expression by Tumor Necrosis
93.	Factor Alpha in Testicular Leydig Co (2000) Abstract.	ells. Possible Involvement in Cell Sur	vival," <i>Biochem Pharmacol.</i> - <u>60(11)</u> :1636-46
	Rudlowski, C., et al., "GLUT1 Messe	nger RNA and Protein Induction Rrel	ates to the Malignant Transformation of
94.	Cervical Cancer." Am J. Clin Pathol.	- 120(5):691-8 (2003) Abstract.	•
95.	Sasaki, T., et al., "Expression and D	istribution of Laminin Alpha1 and Alp	pha2 Chains in Embryonic and Adult Mouse
EXAMINER:		DATE CONSIDERED:	

EXAMINER: Initial if citation considered, whether or not the citation confor	ms with MPEP 609. Draw a line through the citation if not in
conformance and not considered. Include a copy of this form with next col	mmunication to applicant.
*If an asterisk is placed beside the reference number, a copy is not provide	d because the reference was previously cited by or submitted to

to the (d). PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. SV 2228326 v1

	Form PTO-1449 INFORMATION DISCLOSURE STATEMENT (use several sheets if necessary)		Attorney's Docket No.	Application Serial No.
INFO			39780-1618P2C33	09/904,766
INFO			Applicant(s) Avi Ashkenazi et al.	
-10-			Filing Date:	Group Art Unit:
(July 12, 2001	1646
		Tissues: An Immunochemical Appr	oach," Exp Cell Res 275(2):189-99	(2002) Abstract.
	12.		OTHER DOCUMENTS	
		(including a	author, title, date, pertinent pages, et	e)
	96.	Biol Chem 279(25):26581-7 (2004)	Abstract.	rme B Expression in Human Lymphocytes," J
	97.	Shen, Y., et al., "BCL2 Protein Expression Parallels its mRNA level in normal and Maligent B Cells," Blood - 104(9):2936-9 (2004) Abstract.		
		Shinohara, Y., et al., "Quantitative I	Determinations of the Steady Transcr	ipt Levels of Hexokinase Isozymes and
. 10	98.	Glucose Transporter Isoforms in No - 1368(1):129-36 (1998) Abstract.	ormal Rat Tissues and the Malignant	Tumor Cell Line AH130," Biochim Biophys Acta
		Silvers. A.L., et al., "UVA Irradiation	n-Induced Activation of Activator Pro	tein-1 is Correlated with Induced Expression of
	99.	Silvers, A.L., et al., "UVA Irradiation-Induced Activation of Activator Protein-1 is Correlated with Induced Expression of AP-1 Family Memebers in the Human Keratinocyte Cell Line HaCat," <i>Photochem Photbiol.</i> - 75(3):302-10 (2002) Abstract.		
	100.	Song, L., et al., "Rat Kidney Glutamyl Aminopeptidase (aminopeptidase A): Molecular Identity and Cellular Localization." Am J. Physiol 267(4 Pt 2):F546-57 (1994) Abstract.		
	101.	Spaziani, E.P., et al., "Tumor Necrosis Factor-Alpha Upregulates the Prostaglandin E2 EP1 Receptor Subtype and the Cyclooxgenase-2 Isoform in Cultured Amnion WISH Cells," <i>J Interferon Cytokine Res.</i> - 18(12):1039-44 (1998) Abstract.		
	102.	Spika, I., et al., "Transcriptional Activity of Potent Glucocorticoids: Relevance of Glucocorticord Receptor Isoforms and Drug Metabolites," Skin Pharmacol Appl Skin Physiol 16(3):143-50 (2003) Abstract.		
, _	103.	Splinter, P.L., et al., "Specific Inhibition of AQP1 Water Channels in Isolated Rat Intrahepatic Bile Duct Units by Small Interfering RNAs," J Biol Chem - 278(8):6268-74 (2003) Abstract.		
	100.	Stearns, M.E., et al., "Type IV Collagenase (M(r) 72,000) Expression in Human Prostate: Benign and Malignant Tissue," Cancer Res 53(4):878-83 (1993) Abstract.		
t	105.	Stein, R., et al., "The Decompensated Detrusor III: Impact of Bladder Outlet Obstruction on Sarcoplasmic Endoplasmic Reticulum Protein and Gene Expression," J Urol 164(3Pt 2):1026-30 (2000) Abstract.		
	106.	Strickland, I., et al., "TNF-Alpha and IL-8 are Upregulated in the Epidermis of Normal Human Skin after UVB Exposure: Correlation with Nuetrophil Accumulation and E-Selectin Expression," J Invest Dermatol 108(5):763-8 (1997) Abstract.		
	107.	Mediate Acutocrine Fibroblast Proli	iferation," <i>Kidney Int.</i> - <u>57(4)</u> :1521-38	d in Human Renal Fibrogenesis and May (2000) Abstract.
	108.	Takahashi, K., et al., "Adiposity Elevates Plasma MCP-1 Levels Leading to the Increased CD11b-Positive Monocytes in Mice." J Biol. Chem 278(47):46654-60 (2003) Abstract.		
	109.	Takimoto, Y., et al., "Augmented Ex	pression of Neuronal Nitric Oxide Sy Myocardial Infarction in Rats." <i>Circ</i> i	Inthase in the Atria Parasympthetically Illustrian - 105(4):490-6 (2002) Abstract.
	110.	Decreases Heart Rate During Acute Myocardial Infarction in Rats," <i>Circulation</i> - 105(4):490-6 (2002) Abstract. Telek, G., et al., "Differential Upregulation of Cellular Adhesion Molecules at the Sites of Oxidative Stress in Experimental Acute Pancreatitis," <i>J Surg Res.</i> - 96(1):56-67 (2001) Abstract.		
		Timchenko, L., et al., "Myotonic Dys	strophy: An Unstable CTG Repeat in	a Protein Kinase Gene," Semin Cell Biol
	111.	6(1):13-9 (1995) Abstract.		ne Mouse Hepatoma Cell Line Hepa-1 by Various
	112.	Chemicals." Chem Biol. Interact 8	33(2):107-19 (1992) Abstract.	
	113.	Leukemia Cell Lines," Leuk Res 2	?7(12):1115-23 (2003) Abstract.	Cip1) During Differentiation of Human Myeloid
	114.	Van Beers, E.H., et al., "Intestinal C Shows Species Differences and Mo 40 (1998) Abstract.	arbamoyl Phosphate Synthase I in H saic Expression in Duodenum of Bo	uman and Rat. Expression during Development th Species," <i>J Histochem Cytochem.</i> - 46(2):231-
L	-			

	EXAMINER:	DATE CONSIDERED.	
		;;	
	EXAMINER: Initial if citation considered, whether or not the citation conformance and not considered. Include a copy of this form with next of	orms with MPEP 609. Draw a line through the citation if not in	
	*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).		
ш	PTO in a prior application that is identical in the statement and relied upo	on for an earlier filling date under 35 0.5.C. §120. 57 C.F.R. §1.56 (d).	
_	VY EEE0020 V.		

Form PTO-1449 INFORMATION DISCLOSURE STATEMENT		Attorney's Docket No. 39780-1618P2C33	Application Serial No. 09/904,766
		Applicant(s)	00/004,700
			Ashkenazi et al.
		Filing Date:	Group Art Unit:
(use several sheets if necessary)		July 12, 2001	1646
	(including a	OTHER DOCUMENTS uthor, title, date, pertinent pages, etc)
115.	Van Der Wilt, C.L., et al., "Expression Lines, Liver Metastases and Normal	n of Deoxycytidine Kinase in Leukae Liver," <i>Eur J Cancer</i> - <u>39(5)</u> :691-7 (20	mic Cells Compared with Solid Tumour Cell 2003) Abstract.
116.	Waldherr, R., et al., "Expression of Cytokines and Growth Factors in Human Glomerulonephritides," Pediatr Nephrol 7(4):471-8 (1993) Abstract.		
117.	Walmer, D.K., et al., "Malignant Transformation of the Human Endometrium is associated with Overexpression of Lactoferrin Messenger RNA and Protein," <i>Cancer Res.</i> - <u>55(5)</u> :1168-75 (1995) Abstract.		
118.	Wang, J., et al., "Cell Proliferation in Human Soft Tissue Tumors Correlates with Platelet-derived Growth Factor B Chain Expression: An Immunohistochemical and in Situ Hybridization Study," Cancer Res 54(2):560-4 (1994) Abstract.		
119.	and Corresponding Prostatectomy Specimens, Orol Res 2013, 300-13 (2000) Abstract.		
120.	Wang, L.G., et al., "Down-Regulation of Prostate-Specific Antigen Expression by Finasteride through Inhibition of		
121.	Weterman, M.A., et al., "Expression of Calcyclin in Human Melanocytic Lesions," Cancer Res <u>53(24)</u> :6061-6 (1993) Abstract.		
122.	311(2):728-35 (2004) Abstract.		
123.	Wojtaszek, P.A., et al., "Severely Decreased MARCKS Expression Correlates with Ras Reversion but not with Mitogenic Responsiveness" Oncogene - 8(3):755-60 (1993) Abstract.		
124.	Zhong, W., et al., "Expression of Superoxide Dismutases, Catalase, and Glutathione Peroxidase in Glioma Cells," Free Radic Biol Med 27(11-12):1334-45 (1999) Abstract.		
125.	Xi, L., et al., "Expression of Human Telomerase Reverse Transcriptase in Cervix Cancer and its Significance," Zhonghua Fu Chan Ke Za Zhi - 40(6):407-10 (2005) Abstract.		
126.			3 Figure 9-2 of Cell 3rd Cell 3rd at 403
127.	Cell 4th Cell 4th at 364 Cell 4th at 379		6-3 on page 302 Figure 6-90 on page 364 of
128.	Metalloproteinase-1 and Tissue Matr (1997)	ix Metalloproteinase Inhibitor-` Mess	rtes: Expression and Regulation of Matrix enger-RNA and Protein," <i>Thyroid</i> - <u>7(5)</u> :713-724
129.	Human Pathology - 34(7):639-645 (20	003)	ER2/neu Oncogene in Synovial Sarcoma,"
130.	Gnatenko, D.V., et al., "Transcript Pro Expression," Blood - 101(6):2285-229	93 (2003)	
131.	of the Enrichment of Features in the (2002)	Cellular Population of Proteins and	ance Data: An Approach for the Comparison Transcripts," <i>BioinformaticsI</i> - <u>18(4)</u> :585-496
132.	Gromova, I., et al., "Protein Abundancy and mRNA Levels of the Adipocyte-Type Fatty Acid Binding Protein Correlate in Non-Invasive and Invasive Bladder Transitional Cell Carcinomas," <i>International Journal of Oncology</i> - 13(2) 6 pages (1998)		
133.	Hirsch, F.R., et al., "Early Detection of Radiology," Clinical Cancer Researc		s of Recent Advances in Biology and

EXAMINER:	DATE CONSIDERED:	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in		
conformance and not considered. Include a copy of this form with next	communication to applicant.	
*If an asterisk is placed beside the reference number, a copy is not provi	ded because the reference was previously cited by or submitted to the	
PTO in a prior application that is identical in the statement and relied upon	on for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).	

SV 2228326 v1

Form PTO-1449		Attorney's Docket No. 39780-1618P2C33	Application Serial No. 09/904,766
INFORMATI	ON DISCLOSURE STATEMENT	Applicant(s) Avi Ashkenazi et al.	
(use se	everal sheets if necessary)	Filing Date: July 12, 2001	Group Art Unit: 1646
		OTHER DOCUMENTS author, title, date, pertinent pages, et	
134	Holten-Andersen M.D. et al. "Loc	alization of Tissue Inhibitor of Metallo	proteinases 1 (TIMP-1) in Human Colorectal
135	Kuo, C.C., et al. "A Transcriptomic and Proteomic Analysis of the Effect of CpG-ODN on Human THP-1 Monocytic		
136	1 5 0 11 (4007 0 1/1 -4 047 040		
137	Meric, F., et al., "Translation Initiation in Cancer: A Novel Target for Therapy," <i>Molecular Cancer Therapeutics</i> - 1:971-979 (2002)		
138	Munaut, C., et al., "Vascular Endothelial Growth Factor Expression Correlates With Matrix Metalloproteinases MT1-NMP, MNP-2 and NMP-9 in Human Glioblastomas," Int. J. Cancer - 106:848-855 (2003)		
139	Wang, J., et al., "Expression of Cadherins and Catenins in Paired Tumor and non-Neoplastic Primary Prostate Cultures and Corresponding Prostatectomy Specimens," Urol Resl - 28:308-315 (2000)		
140.	Zhigang, Z., et al., "Prostate Stem of Role in Prostate Carinogenesis and	Cell Antigen (PSCA) Express in Huma d Progession of Prostate Cancer," <i>Wo</i>	n Prostate Cancer Tissues and its Potential orld Journal of Surgical Oncology - 2-13 (2004)
	·		
	·		
			·
	· · · · · · · · · · · · · · · · · · ·		
	1		

EXAMINER:	DATE CONSIDERED:	
	·	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.		
*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).		
SV 2228326 v1		